Key result
Cisplatin-based chemotherapy for testicular cancer significantly reduced left ventricular diastolic function, decreasing the E/A ratio from 1.87 to 1.64 at 3 months.
Why the study?
Does cisplatin-based chemotherapy induce acute alterations in cardiac function and metabolic parameters in patients with testicular cancer?
Observational (n=14)
No
Does cisplatin-based chemotherapy induce acute alterations in cardiac function and metabolic parameters in patients with testicular cancer?
Absolute Event Rate: 1.64% vs 1.87%
p-value: p=0.009
Cisplatin-based chemotherapy for testicular cancer induces acute subclinical deterioration in left ventricular diastolic function and unfavorable metabolic changes within 3 months of treatment initiation.
No takes yet. Share an insight, caveat, or question.
May warrant echocardiographic monitoring during cisplatin therapy; leaves open long-term cardiotoxicity risks.
Schinkel et al. (2013) conducted an observational in Testicular cancer (n=14). Cisplatin-based chemotherapy (BEP) vs. Baseline (pre-chemotherapy) was evaluated on Left ventricular E/A ratio (diastolic function) (p=0.009). Cisplatin-based chemotherapy for testicular cancer significantly reduced left ventricular diastolic function, decreasing the E/A ratio from 1.87 to 1.64 at 3 months.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: